India's Taxation of Co-Marketing Agreements: Missteps in the Revenue vs. Capital Receipt Distinction

Introduction. Around the turn of the millennium, Pfizer, the global pharmaceutical giant, entered into a co-marketing agreement with Shantha Biotechnics to distribute Shantha's revolutionary Hepatitis B vaccine “Shanvac-B” under the brand name "HepaShield" in India. At the time, the cost of a hepatitis-B vaccine dose put it well out of the reach of most affected Indians. Shantha’s novel manufacturing processes helped reduce the cost of the vaccine to less than $1/dose. The partnership with Pfizer leveraged Pfizer's extensive distribution network and marketing expertise, facilitating broader reach of the vaccine across India.

More than two decades later, in Comm’r of Income Tax v Satiofi Healthcare[1], the Telangana High Court weighed in on the taxability of the payments Pfizer made to Shantha under the co-marketing agreement. The questions revolve around a bedrock principle of Indian income tax law – the distinction between revenue receipts and capital receipts.

The capital/revenue receipt distinction, in brief. Under Indian income tax law, the distinction between capital receipts and revenue receipts lies in their nature and taxability. Capital receipts are typically non-recurring and arise from transactions affecting a taxpayer's capital structure, such as proceeds from the sale of a capital asset, loans, or investments. These are generally not taxable unless specifically charged to tax, like capital gains. On the other hand, revenue receipts are recurring in nature and arise in the normal course of business or profession, such as income from sales, services, rent, or interest. Revenue receipts are fully taxable as part of the taxpayer's income. The classification is crucial because it determines the applicability of tax provisions, and misclassification can lead to disputes with tax authorities.

Co-marketing agreements, generally. A co-marketing arrangement in the pharmaceutical industry is a strategic partnership between two companies to market and promote a specific drug or pharmaceutical product. Often, the companies market the product under their own brand names while sharing the same underlying drug or formulation. A co-marketing arrangement allows the product developer or manufacturer to gain access to new markets, reduce marketing costs, and leverage the co-marketer's expertise and distribution network. The co-marketer benefits from an exclusive, potentially high-demand product, gaining a competitive edge and potential revenue growth.

Shantha/Pfizer co-marketing agreement, specifically. Pfizer was appointed the exclusive co-marketer for the product (Hepatitis-B vaccines) in the specified territory, thereby obtaining what the agreement characterized as a “right to compete” with Shantha.[2] In addition, Pfizer received an option to co-market new Hepatitis-B vaccines (the “Co-marketing Option”) and priority rights in negotiating over other products Shantha developed in future (the “Priority Right”).[3] The agreement identified a specific amount (the “Disputed Amount”) that Pfizer would pay to Shantha in consideration for its appointment as exclusive co-marketer, the Co-marketing Option and the Priority Right, in contradistinction to the amounts payable by Pfizer for supply of manufactured Shanvac-B/Hepashield vaccine doses, which both parties agreed were taxable revenue receipts.[4]

Shantha took the position that the Disputed Amount constituted a non-taxable capital receipt and did not disclose it on its income-tax return. The Income Tax Department took the view that the Disputed Amount was a taxable revenue receipt and issued a Section 148 notice of reassessment. The Department was successful before the first (administrative) appellate authority, but the second (quasi-judicial) appellate authority held in favor of Shantha.

What the High Court said. The court held in favor of the taxpayer, finding that the Disputed Amount was a non-taxable capital receipt.

Analysis. The court found that Pfizer paid Shantha the Disputed Amount because Shantha surrendered its rights in a capital asset i.e., patents and trademarks. It found that the surrender resulted in the “impairment” of Shantha’s “profit making apparatus” and that therefore the Disputed Amount was a non-taxable capital receipt.[5]

The court’s archaic turn of phrase is intentional and harks back to two Supreme Court judgments – Kettlewell Bullen[6] and Gillanders Arbuthnot[7]. These judgments dealt with whether payments received upon the termination of a managing agency[8] were taxable revenue or non-taxable capital receipts. In these cases, the Supreme Court laid down and reiterated the following test to distinguish between revenue and capital receipts:

“Where on a consideration of the circumstances, payment is made to compensate a person for cancellation of a contract which does not affect the trading structure of his business, nor deprive him of what in substance is his source of income, termination of the contract being a normal incident of the business, and such cancellation leaves him free to carry on his trade (freed from the contract terminated) the receipt is revenue: Where by the cancellation of an agency the trading structure of the assessee is impaired, or such cancellation results in loss of what may be regarded as the source of the assessee's income, the payment made to compensate for cancellation of the agency agreement is normally a capital receipt.”

This test has since been cited[9] prolifically and is foundational to the distinction between revenue and capital receipts in India. Let us rewind.

The distinction between capital and revenue receipts first arose under British income tax law, which did not tax capital (including capital gains) until 1965.[10] British income tax law treated revenue receipts as taxable income, while capital receipts were excluded from taxation. This absence of a tax on capital (and capital gains) meant that the differentiation between capital and revenue receipts had huge ramifications since the characterization of a receipt could significantly influence tax liability. The litany of U.K. cases the Supreme Court cited in Kettlewell Bullen reflect this state of affairs and are illustrative of the then ongoing tussle between taxpayers and the H.M.R.C. to characterize receipts as either non-taxable capital or taxable revenue, and the attempts by U.K. courts to establish a clear boundary between the two kinds of receipts.

India’s income tax system, which is based on the principles that underpin the British income tax system, also did not tax capital (and capital gains) till 1947. A tax on capital gains was first introduced in 1947, repealed in 1949, and then reintroduced in 1956.[11] The capital gains tax is extremely broad-based, taxing “any profits or gains arising from the sale, exchange or transfer of a capital asset”.[12] “Capital assets” are defined, almost without limit, to mean “property of any kind (other than agricultural land) held by an assessee, whether or not connected with his business, profession or vocation, but does not include any stock-in-trade, consumable stores or raw materials held for the purpose of his business, profession or vocation”. The introduction of a broad-based tax on capital gains was intentional and aimed at moving India’s income tax system away from the schedular British system, which did not tax capital, towards the more universal system of taxation prevalent in the United States of America, where capital was not automatically exempted from the scope of income taxation.[13]

Kettlewell Bullen and Gillanders Arbuthnot both dealt with tax years to which the newly introduced tax on capital gains did not apply – situations in which distinguishing between capital receipts and revenue receipts continued to have crucial relevance.

However, in years to which the tax on capital gains applies, the distinction between capital and revenue should have much less relevance since both capital gains and business income would be taxable. Of course, if Parliament continues to allow for the taxation of capital gains at a lower preferential rate, as in the case of long-term capital gains, the distinction retains some of its earlier significance, but the controversy then shifts to one about the applicable rate, and not taxability. Yet, despite this, Indian courts continue to rely on the distinction between revenue and capital receipts to declare capital receipts simply outside the scope of the income tax, and to eschew any analysis of whether the capital receipt would be taxable under the capital gains tax. This approach ignores the legislative intent behind the introduction of the capital gains tax.

Given this, the High Court’s leveraging of the distinction between capital and revenue receipts to declare the Disputed Amount a non-taxable capital receipt is highly questionable. Even if characterized as a capital receipt, given the broad definition of ‘capital asset’ and ‘transfer’ under the Income Tax Act, it is very possible that the capital receipt arose out of the transfer of a ‘capital asset.’ The court did not engage with this possibility – despite recognizing that Shatha relinquished i.e., transferred, its rights in capital assets. Although (in my opinion) the court misidentified the capital assets that were transferred as patents and trademarks, that’s beside the point – having determined that capital assets, the court should have found Section 45 of the Income Tax Act (the charging section for capital gains) applicable, or explained why it didn’t apply, The controversy could and should have been limited to whether the proceeds were taxable revenue receipts or taxable capital receipts. The court could and should have restricted any discussion concerning non-taxability to determining whether there was in fact an element of gain embedded in the capital receipt. Instead, the court lazily concludes that the Disputed Amounts were received by Shantha in exchange for the “impairment” of its “profit making apparatus” and that therefore the Disputed Amount was a non-taxable capital receipt.[14]

Relying on another Supreme Court judgment in Guffic Chem v Comm’r of Income tax[15], the court also makes vague reference to restrictive covenants under the comarketing agreement and holds them to constitute an impairment to Shantha’s profit-making apparatus. But Guffic Chem has since been legislatively overruled[16], and the restrictive covenant in question in Guffic Chem was a non-compete restriction. The court in this case did not have a non-compete restriction in mind and viewed the grant of the Co-Marketing Option and Priority Rights as restrictive covenants. These are standard contractual stipulations in co-marketing arrangements in the pharmaceutical industry and equating them with non-compete restrictions, and then using them to establish an “impairment to profit-making structure” to justify a non-taxable capital receipt, is without precedent. Such a holding narrows the tax base, unjustifiably. If this is what the court intended, it should have done a better job of explaining itself.

Conclusion. The way in which the court goes about reaching its conclusion in this case is frankly a little shocking. It ignores historical context and avoids a thorough analysis of applicable law. Given India’s dreams of becoming the ‘pharmacy of the world,’ and the concentration of pharmaceutical industry in Telangana state (where the High Court’s judgments are binding precedent), this decision is likely to have a significant impact on the tax base. I’m not saying that the appointment of Pfizer as co-marketer, and the grant of the Co-Marketing Option and Priority Rights should necessarily be seen as involving a transfer of capital asses (a pre-requisite for capital gains taxation in India), but if it were up to me, I’d appeal this judgement. Hopefully, the Supreme Court will see more sense. Failing that, and this seems likely because the Income Tax Department has hobbled itself by not making these arguments before the High Court or the lower quasi-judicial / administrative appellate authorities, the government should, as part of its revamp of the Income Tax Act, consider making clearer the very limited scope that exists for receipts to ever be regarded as non-taxable capital receipts.

Other Criticism. Here are a few three other aspects of the court’s opinion I find problematic. These are problems common to many court opinions in India, and I highlight them only to begin a conversation, with the hope that they can be addressed.

Mischaracterization of facts. Firstly, the court’s language misrepresents the contents of the co-marketing agreement. The court says that “patents and trademark which have not been obtained by the assessee for the vaccine have been given up for a consideration.” Nothing in the extracts of the co-marketing agreement the court reproduced suggest that this was the case. It is far more likely that, in line with general practice where co-marketing arrangements are concerned, the intellectual property comprised in the hepatitis-B vaccine continued, and the intellectual property underlying any future vaccines / products developed would continue, to vest with Shantha. Pfizer owned, and would own, only the brand name under which it chose to market the hepatitis-B vaccine and any future vaccines / products Shantha developed. It is unclear why the court characterized the effect of the co-marketing agreement in this fashion, especially given that despite recognizing the transfer of these apparent capital assets, it still chose not to apply Section 45 (the capital gains charging section) of the Income Tax Act.

Opaque precedent. Secondly, following the court’s reasoning presents some difficulty. The court references clauses 1.14, 2.2, 3.2, 13.2, 17.1 and 17.2 of the co-marketing agreement but reproduces clauses 2.1, 7.1, 7.2, 8.1, 8.2, 17.1 and 17.2. The court considers these clauses significant, but since India does not require court filings to be publicly available, appreciating that significance becomes impossible. It is a pity, because under Article 215 of the Constitution of India high courts are courts of record whose judgments are meant to serve as binding precedent to subordinate courts within their jurisdiction. That is not possible when the very basis for the judgment is unclear.

Improper fact finding. Thirdly, despite recognizing settled law that restrains high courts from interfering with findings of fact in appeals under S.260A of the Income Tax Act unless shown to be perverse, the court does just that – “perusing” the co-marketing agreement to “gather facts.”[17]

DISCLAIMER: VIEWS ARE PERSONAL. The facts of this case are drawn from the judgment of the Telangana High Court. Because filings are not public in India, and Indian courts seldom require parties to stipulate to facts, it is possible that court’s recitation of the facts, and out interpretation thereof, do not comport with the facts of the case.

[1] Income Tax Tribunal Appeal No. 138 of 2007

[2] Ibid., at para. 15

[3] Ibid. More specifically, both Pfizer’s co-marketing option on future hepatitis-B vaccines and its priority negotiation rights over other products Shantha developed in future required Shantha to (a) keep Pfizer reasonably informed of Shantha’s progress in developing any such vaccine, and (b) give Pfizer access to all registrations and technical information relating to the vaccine.

[4] Ibid.

[5] Supra note 1, at para. 17

[6] Kettlewell Bullen v Comm’r of Income Tax, 53 ITR 261

[7] Gillanders Arbuthnot v Comm’r of Income Tax, AIR 1965 SC 452

[8] The managing agency system in India was a distinctly Indian phenomenon, introduced and popularized during British colonial rule. Under this system, a firm, or a group of individuals (the managing agents) would manage the operations of a company in exchange for a fixed commission, regardless of profitability. This structure gained prominence in the 19th and early 20th centuries due to its suitability for managing large, capital-intensive ventures like tea plantations, jute mills, and textile factories, where the owners were often absentee investors, such as British shareholders. The practice was outlawed by the Companies (Amendment) Act, 1969.

[9] Comm’r of Income Tax v Prabhu Dayal, AIR 1972 SC 386; Patiala Biscuit Manufacturers v Comm’r of Income Tax, (1971) 82 ITR 812 (SC); Ansal Properties v Comm’r of Income Tax, (2012) 347 ITR 647 (Delhi); Comm’r of Income Tax v R. L. Bhargava, (2002) 174 CTR (DEL) 50; Gujco Carriers v Comm’r of Income Tax, (2002) 256 ITR 50 (GUJ); and Comm’r of Income Tax v Manoranjan Pictures ILR 1998 DELHI 197; Oberoi Hotel v Comm’r of Income Tax, AIR (1999) SC 1110; Addl. Comm’r of Income Tax v K.P. Karanth, (1983) 139 ITR 479 (AP) 10; VC Nannapaneni v Comm’r of Income Tax, (2018) 407 ITR 505 (AP); Shiv Raj Gupta v Comm’r of Income Tax, (2021) 11 SCC 58.

[10] https://www.ft.com/content/8c5b0cf5-819f-494b-ac14-ed762dd524d9

[11] A capital gains tax was first introduced by the Income-Tax and Excess Profits Tax (Amendment) Act, 1947, repealed by the Indian Finance Act, 1949, and then reintroduced by the Indian Finance Act (No.3), 1956.

[12] When it was reintroduced in 1956, the tax was extended to also apply to profits or gains that arose from a ‘relinquishment’ of a capital asset. The capital gains tax of today remains largely unchanged – but has been extended by Parliament to include profits or gains that arise from the “extinguishment of any rights” in a capital asset.

[13] See Report of the Select Committee on the Income Tax and Excess Profits Tax (Amendment) Bill, 1947, Minutes of Dissent. See also: Comm’r v Glenshaw Glass, 348 US 426 (1955)

[14] Supra note 1, at para. 17

[15] [2011] 198 Taxman 78 (SC)

[16] See Section 28(va) of the Income Tax Act, inserted by the Finance Act, 2002

[17] Supra note 1, at para. 16